Tessa Romero
Stock Analyst at JP Morgan
(4.15)
# 510
Out of 5,005 analysts
64
Total ratings
46%
Success rate
19.29%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Tessa Romero
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ACAD ACADIA Pharmaceuticals | Maintains: Overweight | $34 → $33 | $21.65 | +52.42% | 10 | Sep 29, 2025 | |
| NMRA Neumora Therapeutics | Downgrades: Underweight | n/a | $1.84 | - | 5 | Sep 16, 2025 | |
| EWTX Edgewise Therapeutics | Maintains: Overweight | $40 → $30 | $15.17 | +97.76% | 10 | Aug 19, 2025 | |
| DYN Dyne Therapeutics | Maintains: Neutral | $10 → $9 | $12.47 | -27.80% | 6 | Jul 15, 2025 | |
| BHVN Biohaven | Maintains: Overweight | $68 → $55 | $15.75 | +249.21% | 7 | Jun 18, 2025 | |
| CYTK Cytokinetics | Maintains: Overweight | $71 → $53 | $60.15 | -11.89% | 5 | Jun 9, 2025 | |
| LXEO Lexeo Therapeutics | Maintains: Overweight | $16 → $10 | $6.50 | +53.85% | 2 | May 30, 2025 | |
| UPB Upstream Bio | Initiates: Overweight | $38 | $18.98 | +100.21% | 1 | Nov 5, 2024 | |
| MCRB Seres Therapeutics | Downgrades: Underweight | n/a | $20.64 | - | 2 | Oct 24, 2024 | |
| SRRK Scholar Rock Holding | Maintains: Overweight | $18 → $31 | $38.80 | -20.10% | 5 | Oct 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $32 → $29 | $13.60 | +113.24% | 3 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Neutral | $46 | $40.55 | +13.44% | 6 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $54 → $55 | $39.02 | +40.95% | 2 | Apr 25, 2023 |
ACADIA Pharmaceuticals
Sep 29, 2025
Maintains: Overweight
Price Target: $34 → $33
Current: $21.65
Upside: +52.42%
Neumora Therapeutics
Sep 16, 2025
Downgrades: Underweight
Price Target: n/a
Current: $1.84
Upside: -
Edgewise Therapeutics
Aug 19, 2025
Maintains: Overweight
Price Target: $40 → $30
Current: $15.17
Upside: +97.76%
Dyne Therapeutics
Jul 15, 2025
Maintains: Neutral
Price Target: $10 → $9
Current: $12.47
Upside: -27.80%
Biohaven
Jun 18, 2025
Maintains: Overweight
Price Target: $68 → $55
Current: $15.75
Upside: +249.21%
Cytokinetics
Jun 9, 2025
Maintains: Overweight
Price Target: $71 → $53
Current: $60.15
Upside: -11.89%
Lexeo Therapeutics
May 30, 2025
Maintains: Overweight
Price Target: $16 → $10
Current: $6.50
Upside: +53.85%
Upstream Bio
Nov 5, 2024
Initiates: Overweight
Price Target: $38
Current: $18.98
Upside: +100.21%
Seres Therapeutics
Oct 24, 2024
Downgrades: Underweight
Price Target: n/a
Current: $20.64
Upside: -
Scholar Rock Holding
Oct 14, 2024
Maintains: Overweight
Price Target: $18 → $31
Current: $38.80
Upside: -20.10%
Aug 13, 2024
Maintains: Overweight
Price Target: $32 → $29
Current: $13.60
Upside: +113.24%
Jun 13, 2024
Reinstates: Neutral
Price Target: $46
Current: $40.55
Upside: +13.44%
Apr 25, 2023
Maintains: Overweight
Price Target: $54 → $55
Current: $39.02
Upside: +40.95%